AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03849027 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: The sham inhaler will have one droplet of methoxyflurane applied to the outer surface, but no drug in the vaporization chamber to give off the prominent odour with no analgesic effect, partially blinding the participants to the test.
Study NCT02274701 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holistic Needs Assessment
Description: An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
Study NCT01124630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
Study NCT01124630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
Study NCT01992159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study NCT04322344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escin
Description: treatment with escin or escinate sodium
Study NCT04322344 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: standard therapy
Description: antiviral drugs
Study NCT04322344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard therapy
Description: antiviral drugs
Study NCT00507117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lunesta
Description: Lunesta 3mg prior to PSG
Study NCT00507117 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo control
Description: matching placebo
Study NCT02623647 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: stereotactic body radiotherapy SBRT
Description: 40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
Study NCT02586350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Study NCT02586350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo p.o. qd
Study NCT03896594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL237
Description: Experimental
Study NCT03896594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Oral Tablet
Description: placebo with same properties except for active ingredient
Study NCT01306838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MicroLipid and fish oil
Description: Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
Study NCT01306838 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine care
Description: Routine care
Study NCT04272216 — intervention group
Intervention type: DEVICE
Intervention: Treatment with HydroPearl via radial access
Description: This is an observational study collecting data on patients who are already being treated with HydroPearl on-label per standard of care.
Study NCT03997019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: opioid analgesia
Description: opioid analgesia will be used with general anaesthesia
Study NCT03997019 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP block
Description: ultrasound guided ESP Block before anaesthesia induction
Study NCT02451163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: wheat polysaccharides
Description: Consumed once daily for 12 weeks.
Study NCT00810797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: One year after completion of study treatment
Study NCT00810797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies
Study NCT02214979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Ramipril
Description: fixed dose combination tablet
Study NCT02214979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan
Study NCT02214979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril capsule
Study NCT02214979 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ramipril tablet
Study NCT01269567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laying and management of the drain (strictly randomized arm with drainage)
Description: At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit \< 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.
Study NCT01269567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No pelvic drainage
Description: no aspiration drain at the end of intervention
Study NCT03527901 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: GCF collection with aMMP-8 chair side test
Study NCT03527901 — intervention group
Intervention type: OTHER
Intervention: Saliva collection
Study NCT02451163 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: Consumed once daily for 12 weeks.
Study NCT03585556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF
Description: Intravitreal injection of anti-VEGF at Day 0 then monthly as needed
Study NCT03585556 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intravitreal AAVCAGsCD59
Description: An intravitreal injection of AAVCAGsCD59 will occur at Day 7 once
Study NCT03585556 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral prednisolone
Description: A 7 day tapering dose of oral prednisone will be taken at Day 30 by all patients
Study NCT03671954 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Strengthening Exercises
Description: The intervention group will perform unsupervised home strengthening exercises for the hip abductors in addition to standard physical therapy, while the control group will receive standard physical therapy alone.
Study NCT03671954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Physical Therapy
Description: Physician determined standard of care for individual TKA patients.
Study NCT03671954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physical Therapy
Description: Physician determined standard of care for individual TKA patients.
Study NCT03671954 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative Assessments
Description: Assessments will include:~* TUG (timed up and go test) >12 sec indicates increased fall risk~* Tandem balance test \< 10 sec indicates increased fall risk~* Sit to Stand test (age based norms)~* Knee Range Of Motion (ROM)~* Quadriceps and hamstring strength (MMT or hand held dynamometer)~* Lower Extremity Functional Score (LEFS questionnaire)
Study NCT00979147 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TKA surgery with modular polished tibial baseplate/XLK design
Description: TKA surgery with modular polished tibial baseplate/XLK design
Study NCT00979147 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TKA surgery with the nonmodular APT/GVF design
Description: TKA surgery with the nonmodular APT/GVF design
Study NCT00979147 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: P.F.C.® Sigma Knee System
Description: P.F.C.® Sigma Knee System with modular XLK poly
Study NCT00979147 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: P.F.C.® Sigma Knee System
Description: P.F.C. ® Sigma Knee System with an all-poly GVF tibia
Study NCT02180321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
Study NCT02180321 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: 10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
Study NCT03776552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rapid weight loss (RWL) program
Description: 16-week rapid weight loss (RWL) program (8-week low energy diet (LED) followed by 8-week gradual increased energy intake) and a subsequent 36-week weight-maintenance follow-up
Study NCT03776552 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gradual weight loss (GWL) program
Description: 16-week gradual weight loss (GWL) program (moderate calorie restriction) and a subsequent 36-week weight-maintenance follow-up
Study NCT02491099 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
Study NCT03328026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SV-BR-1-GM
Description: SV-BR-1-GM inoculation intradermally at 4 sites.
Study NCT03328026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose cyclophosphamide
Description: Pretreatment with low dose cyclophosphamide 2-3 days prior to SV-BR-1-GM inoculation.
Study NCT03328026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon Inoculation
Description: Post-inoculation low dose Interferon into the vaccination sites \~2 days after SV-BR-1-GM inoculation.
Study NCT03328026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: retifanlimab
Description: retifanlimab 375mg administered as an intravenous infusion over 30-60 minutes every 3 weeks per randomization
Study NCT01260324 — intervention group
Intervention type: OTHER
Intervention: No intervention given in this observational study
Description: No intervention given in this observational study
Study NCT03309111 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISB 1342
Description: ISB-1342 is CD38 x CD3 BEAT® 1.0 bispecific antibody. ISB 1342 is administered by intravenous (IV) infusion or subcutaneous injection (SC)
Study NCT01163565 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ligasure Device
Description: Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
Study NCT01529112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Study NCT01529112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenvatinib matched placebo
Study NCT01529112 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BSC
Study NCT01529112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BSC
Study NCT00144508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRA (Tocilizumab)
Description: 8mg /kg /4week for 52 weeks
Study NCT00144508 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: current treatment
Description: continue current treatment
Study NCT00983957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-790052
Description: Tablets, Oral, 60 mg, once daily, 10 days
Study NCT00983957 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ortho Tri-Cyclen®
Description: Tablets, Oral, once daily, 78 days
Study NCT03268161 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mutational analysis of clonal B cells
Description: Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.~Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought.
Study NCT00421733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar (paricalcitol ) capsules
Description: Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
Study NCT00421733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zemplar (paricalcitol) capsules
Description: Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
Study NCT00421733 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Group 1 - Placebo once daily (two placebo capsules once daily)
Study NCT03848351 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Oral Hygiene Instruction (OHI)
Description: OHI will be given focusing on electric toothbrushing as first instance and subsequently focusing on interdental cleaning. OHI will be delivered by trained dental hygienist/periodontist. In the first phase the clinician will explain and show the technique to the patient. The patient will be then invited to perform the technique. Each phase will be assisted and monitored by the clinician. Overall, this sequence may be repeated as many times as the clinician would deem appropriate.
Study NCT01992159 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT01146210 — intervention group
Intervention type: OTHER
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03848351 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Professional supragingival scaling and polishing
Description: Patients will receive a session of professional supragingival scaling and polishing, that consists of removal of dental plaque and dental calculus from the surface of a tooth, with great care in performing exclusively coronal maneuver. No instrumentation or exploring of the gingival crevice/ sulcus will be performed. Instrumentation will be performed by a trained dental hygienist/periodontist.
Study NCT02157051 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Description: Given ID
Study NCT02157051 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03492138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONC201
Description: 625mg
Study NCT03492138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Dose to be determined in Phase 1 of study
Study NCT03492138 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40mg
Study NCT03413423 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BAT-CS
Description: All participants will receive one hour standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
Study NCT03413423 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking Cessation and Health & Wellness
Description: All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking Cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
Study NCT02722239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xigduo XR
Description: a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
Study NCT03809546 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dronabinol
Description: THC (Marinol® \[dronabinol\]; Solvay Pharmaceuticals) will be orally administered in doses of 7.5 mg and 15 mg, in opaque capsules with dextrose filler. Placebo capsules contain only dextrose. These doses of THC are known to produce performance impairments as well as subjective intoxication with little to no adverse reactions in experienced occasional, but non-daily cannabis users (Ménétrey et al., 2005; Issa et al. 2016).
Study NCT03809546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dextrose
Description: We are administering dextrose to health volunteers for our placebo group
Study NCT01613235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Induced hypertension
Description: Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
Study NCT02762864 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: platelet (P2Y12) reaction units
Description: VerifyNow P2Y12 assay point-of-care testing
Study NCT02762864 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: platelet (P2Y12) reaction units
Description: VerifyNow P2Y12 assay point-of-care testing
Study NCT02762864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ticagrelor
Description: Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
Study NCT02762864 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator
Description: dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
Study NCT02762864 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
Study NCT01223248 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IGIMRT using a single dose of 24 Gy
Description: Pts in both the hypofractionated \& single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI \& DCE-MRI pretreatment for both arms \& 1 hour after their initial treatment for single fraction pts, \& within one hour of their initial \& final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule \& MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, \& approximately 24 hours \[MCPG2.3\]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.